Has Gerard McNulty, MD received payments from drug or device companies?

Yes. Drug and device makers reported $26,872 in general payments to Gerard McNulty, MD across 1,403 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Gerard McNulty, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Gerard McNulty, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Gerard McNulty, MD

Internal Medicine · Tulsa, OKNPI 1073592945

Payments from drug & device makers

$26,872in general payments, 2019–2025

Across 1,403 payments — averaging $19.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$3K
AstraZeneca$3K
GSK$2K
Boehringer Ingelheim$2K
Novo Nordisk$2K
Lilly USA, LLC$2K
plus $14K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	184	$3,124
AstraZeneca(2 entities)	93	$2,808
GSK	119	$2,021
Boehringer Ingelheim	82	$1,774
Novo Nordisk	85	$1,731
Lilly USA, LLC	91	$1,508
Pfizer	79	$1,296
Amgen	58	$888
Johnson & Johnson	55	$883
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	45	$707
Novartis	42	$667
Otsuka America Pharmaceutical, Inc.	29	$662
Lundbeck LLC	34	$654
Merck	40	$586
Axsome Therapeutics, Inc.	19	$546
Amarin Pharma, Inc.	29	$529
Phathom Pharmaceuticals, Inc.	14	$501
Eisai Inc.	22	$499
Sanofi-aventis U.S. LLC	20	$462
Takeda Pharmaceuticals U.S.A., Inc.	26	$446
Bayer	24	$436
Idorsia Pharmaceuticals US Inc	19	$432
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	12	$347
Sumitomo Pharma America, Inc.	24	$343
Astellas Pharma US Inc	15	$303
Exact Sciences	12	$197
Abbott	13	$194
Vanda Pharmaceuticals Inc.	4	$193
Esperion Therapeutics, Inc.	10	$187
Arbor Pharmaceuticals, Inc.	10	$168
Kowa Pharmaceuticals America, Inc.	10	$154
Jazz Pharmaceuticals Inc.	9	$139
Insulet Corporation	1	$139
Almatica Pharma LLC	7	$131
E.r. Squibb & Sons, L.L.C.	8	$128
Lexicon Pharmaceuticals, Inc.	2	$111
Biohaven Pharmaceutical Holding Company Ltd.	5	$88
Mylan Specialty L.p.	4	$83
Paratek Pharmaceuticals, Inc.	4	$66
Sunovion Pharmaceuticals Inc.	6	$65
Boston Scientific	3	$54
Corium, LLC	3	$54
Althera Pharmaceuticals LLC	4	$52
Dexcom, Inc.	2	$50
Advanced Respiratory, Inc	2	$46
Viatris Specialty LLC	2	$45
Daiichi Sankyo Inc.	2	$44
Biogen	2	$39
Endo Pharmaceuticals Inc.	2	$39
Baxter Healthcare	2	$34
Genentech USA, Inc.	2	$30
Biohaven Pharmaceuticals, Inc.	2	$26
Amneal Pharmaceuticals LLC	1	$26
Zyla Life Sciences, Inc.	2	$22
Ascendis Pharma Endocrinology Inc	1	$21
Azurity Pharmaceuticals, Inc.	1	$20
Sanofi Pasteur Inc.	1	$19
Xeris Pharmaceuticals, Inc.	1	$16
Dynavax Technologies Corporation	1	$15
Therapeuticsmd, Inc.	1	$14

How this compares

$26,872 in reported general payments places this provider in the 95th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma →

Medicare billing

Part B allowed, 2024

$93,622

Medicare patients

426

Services billed

1,682

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Tulsa

Al-Ola AbdallahTulsa$10.1M
Melita TateTulsa$9.1M
Renae MayerTulsa$766K
Mousumi SomTulsa$391K
Jesse RichardsTulsa$279K
Madhuri LadTulsa$195K
Lam leTulsa$191K
Stacy ChronisterTulsa$163K
Katherine CookTulsa$41K
Layth Al AttarTulsa$35K

See the full list for Oklahoma →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →